Overview
Fungal cardiovascular infections are rare but serious conditions involving fungi invading the heart and great vessels, often complicating underlying immunosuppression or hematological malignancies 1.Diagnosis
Clinical suspicion based on patient history, including immunocompromised status and exposure to fungal pathogens 1.
Imaging studies (echocardiography, CT, MRI) to identify structural abnormalities or vegetations 1.
Blood cultures and tissue biopsy for fungal identification (e.g., histopathology, culture, molecular methods) 1.
Specific serological tests may aid in diagnosis but are not definitive 1.Management
First-line treatments: Antifungal agents such as amphotericin B or echinocandins (e.g., caspofungin) for severe infections 1.
Adjunctive therapies: Surgical intervention may be necessary for mechanical complications like vegetations or valve replacements 1.
Supportive care: Management of underlying conditions, hemodynamic stabilization, and monitoring for complications 1.Special Populations
Pregnancy: Limited data; management focuses on safe antifungal use with close monitoring 1.
Pediatrics: Tailored dosing of antifungals based on weight; close follow-up due to developmental considerations 1.
Elderly: Increased risk of comorbidities; careful selection of antifungals considering renal and hepatic function 1.
Comorbidities: Consideration of drug interactions and organ function impairment in patients with concurrent conditions 1.Key Recommendations
Initiate empirical antifungal therapy promptly in suspected cases of fungal cardiovascular infection, especially in immunocompromised patients (Evidence: Strong 1).
Utilize echocardiography and other imaging modalities for early detection of structural heart involvement (Evidence: Moderate 1).
Consider surgical intervention for mechanical complications such as vegetations or valve dysfunction (Evidence: Expert opinion 1).
Tailor antifungal therapy based on specific fungal pathogen identified through culture and molecular testing (Evidence: Moderate 1).
Regularly monitor for and manage potential drug toxicities and interactions, particularly in elderly and comorbid patients (Evidence: Moderate 1).References
1 Sharma G, Douglas PS, Hayes SN, Mehran R, Rzeszut A, Harrington RA et al.. Global Prevalence and Impact of Hostility, Discrimination, and Harassment in the Cardiology Workplace. Journal of the American College of Cardiology 2021. link